# Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC

> **NCT04973306** · PHASE2,PHASE3 · RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 176 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma Stage II
- Esophageal Squamous Cell Carcinoma Stage III

## Interventions

- **PROCEDURE:** Neoadjuvant Chemoradiotherapy
- **DRUG:** Tislelizumab
- **PROCEDURE:** Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)

## Key facts

- **NCT ID:** NCT04973306
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-02
- **Primary completion:** 2024-07
- **Final completion:** 2027-07
- **Target enrollment:** 176 (ESTIMATED)
- **Last updated:** 2022-06-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04973306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04973306, "Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04973306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*